Assessing Insulin Clearance in Mice via In Situ Liver Perfusion

Summary

Hepatic insulin clearance is critical for regulating glucose homeostasis. This article describes a user-friendly hepatic perfusion procedure for directly evaluating the hepatic insulin clearance rate in situ in mice.

Abstract

Hepatic insulin clearance is essential for maintaining glucose homeostasis and is closely linked to metabolic disorders such as obesity, insulin resistance, and diabetes. Accurate measurement of insulin clearance is vital for understanding the underlying mechanisms of these conditions. This protocol presents a straightforward and user-friendly hepatic perfusion procedure in mice, specifically designed to directly evaluate the hepatic insulin clearance rate. The method involves precise cannulation of the portal vein and suprahepatic inferior vena cava to create an in situ perfusion system that mimics physiological conditions. The protocol guides researchers through every stage of the procedure, from surgical preparation and setting up the perfusion system to sample collection and analysis. Detailed instructions are provided, along with representative results and important tips for optimizing the procedure. A video tutorial accompanies the written protocol, offering visually in-depth instructions and illustrations, making it an accessible and comprehensive reference for scientists exploring the molecular mechanisms behind hepatic insulin metabolism and clearance.

Introduction

The discovery of insulin has become one of the milestones of the last century. Much is known about the regulation of insulin synthesis, secretion, and its physiological functions in metabolic tissues. However, there has been less focus on insulin degradation and its regulatory mechanisms. Insulin metabolism can be understood as the interplay between beta cell function, insulin resistance (IR) or sensitivity, and insulin clearance. Alongside insulin secretion, hepatic insulin clearance plays a crucial role in maintaining the homeostatic level of insulin necessary for reaching peripheral target tissues and facilitating proper insulin action¹. Multiple studies have identified impaired insulin clearance as a crucial factor in the pathogenesis of hyperinsulinemia in metabolic syndrome, as well as in other conditions such as type 2 diabetes^2,3, nonalcoholic steatohepatitis⁴, and polycystic ovarian syndrome⁵. Thus, hyperinsulinemia secondary to reduced clearance may play a role in the pathogenesis of metabolic disease. Strategies that improve insulin clearance have the potential to reverse the unfavorable impacts of hyperinsulinemia in these individuals.

Insulin has a unique pattern of distribution. The level of circulating plasma insulin depends on the equilibrium between insulin secretion and removal. The pancreas secretes insulin into the portal vein in a pulsatile manner, directing it to the hepatocytes. As the first organ to encounter insulin secretion, the liver degrades the majority of insulin during its first passage, accounting for 60%-70% of total insulin⁶. The remaining insulin exits the liver through the hepatic vein, entering the systemic circulation, where it is partially utilized by peripheral tissues (primarily muscle, adipose tissue, and kidneys) before being further extracted by the liver during its second pass through the hepatic artery⁷.

The precise measurement of insulin clearance is crucial. Directly measuring hepatic insulin clearance in human studies is challenging because obtaining blood samples from the portal and hepatic veins is difficult. Both direct and indirect methods are used to estimate insulin clearance in humans and animal models. Approximately three strategies are employed to measure insulin clearance indirectly. The assessments most frequently utilized in clinical practice involve methods based on the C-peptide/insulin molar ratio⁸. This approach is grounded in the equimolar secretion of both peptides and the absence of C-peptide extraction by the liver⁹. The second group of methods depends on the mathematical analysis of plasma decay curves of insulin after a known and specific input of the hormone into the circulation^2,10,11. The third method is based on the fact that the infusion of insulin at a constant rate leads to stable levels of the hormone in the blood, where the removal rate matches the administration rate¹². These indirect methods primarily reflect overall insulin clearance in the body. Given that the liver is the primary site of insulin clearance and plays a crucial role in this process, it is essential to directly evaluate hepatic insulin clearance.

Previous studies have directly measured hepatic insulin extraction in healthy dogs^13,14. Studies have also used an isolated perfused rat liver model to assess insulin extraction from the liver^15,16. Due to the high availability of genetically modified strains, mice serve as valuable models for investigating molecular pathways. A few studies¹⁷ have utilized liver perfusion to directly assess hepatic insulin clearance in a mouse model. In these studies, a perfusate containing human insulin is infused into the portal vein and collected from the inferior vena cava. The proportion of insulin absorbed by the liver indicates its clearance. The liver perfusion technique maintains the liver under near-physiological conditions by circulating a warm, oxygenated, and nutrient-enriched perfusate through the liver vasculature. However, there is insufficient practical guidance and essential tips for advancing and disseminating this technique.

Thus, while hepatic insulin clearance has received increasing attention, its role in disorders, as well as its molecular mechanisms, remains unclear¹⁸. Therefore, advanced techniques are greatly needed in the field of scientific research. This protocol establishes a detailed modified hepatic perfusion procedure in mice for evaluating hepatic insulin clearance. Additionally, this method can also be used to study the effects of drugs on the liver, including the first-pass effect, drug transport processes, and various other aspects.

Protocol

This protocol was approved by the Nanjing Medical University Animal Care and Use Committee (IACUC-2105018) and followed the guidelines of the Institutional Animal Care and Use Committee. All C57BL/6N mice were maintained on a 12-h light/dark cycle with free access to food and water. Six-week-old mice were randomly divided into a Chow diet (CD) group and a High-fat diet (HFD) group. The HFD group was fed a 60% high-fat diet and continued on this diet until 10 weeks of age. The average body weight was 28.55 g ± 1.2 g for the HFD group and 24.3 g ± 0.48 g for the control group. The details of the reagents and equipment used in this study are listed in the Table of Materials.

1. Preparation

1. Perform requisite sterilization of surgical instruments and consumables through autoclaving.
2. Place the surgical instruments, 6-0 silk suture, sterile small cotton applicator, sodium chloride injection (500 mL), cotton swabs, and sponges appropriately on the operation table.
3. Prepare 30 mL of heparinized saline with a final concentration of 200 IU/mL.
4. Prepare two silicone tubes with an inner diameter of 0.31 mm and an outer diameter of 0.64 mm; one 4 cm in length for use as the portal vein catheter, and the other 10 cm in length for use as the inferior vena cava catheter.
5. Prepare the Krebs-Henseleit (KRBH) perfusion buffer containing 5.0 mmol/L glucose and 0.25% BSA.
6. Prepare the Krebs-Henseleit (KRBH) perfusion buffer containing 5.0 mmol/L glucose, 0.25% BSA, and 4.0 ng/mL human insulin.
7. Set up the liver perfusion system. Figure 1 shows the main components of the liver perfusion system.

2. Surgical catheterization

1. Prepare the anesthetic mixture by following the steps below:
   1. Dilute Zoletil 50 (250 mg/5 mL) 10 times with 0.9% sodium chloride solution.
   2. Dilute Xylazine hydrochloride (200 mg/2 mL) 10 times with 0.9% sodium chloride solution.
   3. Mix the 0.5% Zoletil 50 solution with the 1% Xylazine hydrochloride solution in a 1:1 ratio.
2. Anesthetize the mice.
   1. Check and record the mouse's body weight. Administer the anesthetic mixture via intraperitoneal injection at a dose of 5 mL/kg body weight (2.5 mg/mL Zoletil 50; 5 mg/mL Xylazine hydrochloride). The onset of anesthesia typically occurs within 5-10 min post-injection, indicated by the loss of the righting reflex and reduced response to external stimuli.
   2. Transfer the mouse to the operation table. Secure the limbs using adhesive tape. Administer 2.5 U/g heparin intraperitoneally to achieve heparinization.
   3. Use an electric shaver to trim the fur on the abdominal skin and disinfect the area with a povidone-iodine solution.
3. Perform portal vein catheterization.
   1. Make a 4 cm longitudinal incision from the lower abdomen toward the xiphoid process along the mid-abdominal line. Carefully cut the peritoneum with scissors to avoid damaging visceral organs. Insert the mouse abdominal retractor to expose the surgical field.
   2. Move the intestines to the right to reveal the portal vein, the right kidney, and the inferior vena cava (Figure 2A). Use artery forceps to clamp the vena cava at the upper edge of the kidney.
   3. Isolate the portal vein (Figure 2A) and ligate the distal end with a 6-0 silk suture. Loosely tie another suture on the proximal end of the exposed vessel.
   4. Make an incision near the ligated end with spring scissors and insert the catheter. Advance the catheter through the incision up to the level of the portal bifurcation.
   5. Secure both ligatures around the catheter and confirm proper sampling by connecting the free end of the catheter to a sampling syringe. Flush with heparinized saline and clamp the catheter (Figure 2C).
   6. Remove the traction device and reset the intestines. Cover the surgical area with saline-soaked sterile gauze or cotton.
4. Perform suprahepatic inferior vena cava catheterization.
   1. Make an incision along the sternum from the xiphoid process, exposing the sternum.
   2. Vertically cut open the sternum and cut through the diaphragm along the rib margin to expose the thoracic cavity.
   3. Expose and isolate the suprahepatic inferior vena cava (Figure 2B). Carefully ligate the distal end with a 6-0 silk suture. Loosely tie another suture on the proximal end of the vessel.
   4. Make an incision just below the ligated end with spring scissors and insert a 10 cm catheter. Advance the catheter until the tip of the catheter is close to the liver and tie both ligatures securely. Confirm proper sampling and clamp the free end of the catheter (Figure 2D).
   5. Rinse the surgical area with saline solution. Cover the surface with saline-soaked sterile gauze.

3. Liver perfusion

1. Euthanize the mouse by using an overdose of anesthetic and thoracotomy in accordance with institutional guidelines for animal care and use, ensuring that all procedures are performed in a manner that minimizes suffering.
2. Set up the liver perfusion system, which includes an oxygenator, a temperature modulation device, an infusion pump, and infusion tubes, as shown in Figure 1.
3. Provide a continuous gas flow of 95% oxygen and 5% carbon dioxide to the oxygenator.
4. Turn on the water bath and prewarm the organ chamber to 37 °C.
5. Prepare the KRBH perfusion buffer with and without insulin. Prime the tubing system with the perfusion buffer incubated in a water bath at 37 °C.
   NOTE: The KRBH is free of BSA and glucose. The KRBH perfusion buffer without human insulin contains 5.0 mmol/L glucose and 0.25% BSA, while the KRBH perfusion buffer with human insulin contains 5.0 mmol/L glucose, 0.25% BSA, and 4.0 ng/mL human insulin.
6. Place the mouse in a container with the environmental temperature maintained at approximately 37 °C. Use a warming pad to maintain the body temperature at 37 °C.
7. Infuse the KRBH buffer through the portal vein catheter. Set the infusion rate at 0.2 mL/min via a mini pump.
8. Observe that the liver turns pale within seconds, indicating that the perfusion buffer is flowing through the liver. To flush out more remaining blood cells in the liver, pause the infusion for 1 min at the 4-min and 8-min time points, starting the timing at the beginning of the perfusion.
9. Perfuse the liver with KRBH buffer for a total of 10 min (excluding the two 1-min pauses), representing the equilibration period. Collect the basal sample from the inferior vena cava catheter.
10. Perfuse the liver with the same solution enriched with insulin (4.0 ng/mL human insulin) for an additional 30 min.
11. Collect all samples from the inferior vena cava tube every 2 min.
12. Record the liver weight after perfusion. Collect liver samples from different lobes, immediately freeze them in liquid nitrogen, and then transfer to -80 °C for storage.
13. Centrifuge all collected perfusion samples at ~1,000 x g for 10 min at 4 °C. Collect the supernatants and transfer them to -80 °C for storage.
    NOTE: The insulin concentration in perfusion samples is measured using human insulin enzyme-linked immunosorbent assay (ELISA) kits.
14. Post-procedure, ensure that all biological waste is disposed of according to safety regulations.

4. Data analysis

1. Present the data in XY graphs showing the insulin concentration output over time.
2. Calculate the average hepatic insulin clearance rate (HICR_AVE) using the following formula:
   HICR_AVE = (1−C_f/C_i) × 100%
   where C_i = initial insulin concentration of infusion buffer, C_f = final average insulin concentration in the last 10 min from suprahepatic inferior vena cava.

Results

This protocol outlines the procedure for liver infusion to calculate hepatic insulin clearance directly. This model is reliable and reproducible. An example of the results obtained from an experiment is shown in Figure 3. After a 10-min equilibration period, KRBH buffer supplemented with 4.0 ng/mL human insulin was perfused through the portal vein for 30 min. Perfusion fluid was collected from the catheter in the suprahepatic inferior vena cava at 2-min intervals, and the concentration of hu...

Discussion

Critical steps in the protocol
The above-described surgical procedures should be performed with gentle care to avoid creating any lesions in the liver. Moreover, the fragile structure of the liver vein vessel wall renders it vulnerable to puncture and subsequent bleeding if not handled with care during cannulation. Softer silicone tubes are utilized in this protocol to minimize damage to blood vessels. It is recommended that catheterization be performed by an experienced surgeon who should practice...

Materials

Name	Company	Catalog Number	Comments
60% high-fat diet	Research Diets, USA	D12492
Alanine aminotransferase Assay Kit	Nanjing Jiancheng Bioengineering Institute	C009-2-1
Anhydrous Glucose	Sangon Biotech	50-99-7	500 G
Aspartate aminotransferase Assay Kit	Nanjing Jiancheng Bioengineering Institute	C010-2-1
Bovine Serum Albumin	GeminiBio	700-107P	Fatty Acid-Free
Contour TS Blood Glucose Meter	Bayer	PH220800019
Contour TS Blood Glucose Test Strips	Bayer	DP38M3F05A
Heparin Sodium	Changzhou Qian hong Bio-pharma	H32022088	12500 U/2mL
Human insulin	Novo Nordisk	S20191007	300 U/3mL
Human insulin immunoassay kit	Ezassay Biotechnology	HM200
KRBH buffer (Sugar, BSA free)	coolaber	SL65501	500 mL
Membrane oxygenator	Xi'an Xijing Medical Appliance	5
Microscopic scissors	Shanghai Jinzhong	YBC020
Micro-serrefine clamp	Ningbo Medical Needle	180709
Microsurgery forceps	Shanghai Jinzhong	WA3010, WA3020
Needle type filter	N-buliv	LG05-133-2
Povidone-iodine Solution	Shanghai likang Disinfectant Hi-Tech	20231016J
pump 11 Elite	Harvard Apparatus	PC5 70-4500
Retractor	Globalebio (Beijing) Technology	GEKK-10mm	10 mm
Silicone Tubing	scientific commodities	#BB518-12	0.31 mm × 0.64 mm
Silicone Tubing	Fisher Scientific	#11-189-15A	ID 0.5 mm
Sodium Chloride Injection	Baxter	S2402023	4.5 g/500 mL
Surgical silk suture	Yangzhou Huanyu Medical Equipment	6-0
Temperature modulation	Xi'an Xijing Medical Appliance	6
Thermostatic water bath	Jiaxing Junsi Electronics	HIH-1	220 V 50 HZ
Three-way Joint	YISAI	AQTCY1.6	ID 0.4 mm
Xylazine Hydrochloride Injection	ShengXin	20240106	200 mg/2mL
Zoletil 50	Virbac	WK001	250 mg/5mL